Perspectives

How does this study impact clinical practice?

• Atogepant 170 mg provides a well-tolerated preventative treatment option for patients with migraine and adds to the growing number of CGRP therapies available.
• The potential risk of liver injury from multiple doses of atogepant appears to be relatively low.
• The convenience of an oral therapy could aid treatment compliance while alleviating some of the burden associated with intravenous or subcutaneous administration.